Can Waters bring LC-MS into routine diagnostics with BD’s hospital channel access?

Following its $17.5 billion merger with Becton, Dickinson and Company’s biosciences and diagnostics unit, Waters Corporation is now positioned to make a bold push into clinical diagnostics. By integrating BD’s strong hospital and point-of-care distribution with its own expertise in liquid chromatography-mass spectrometry (LC-MS), Waters is signaling its intent to mainstream a technology that, until now, has largely remained confined to research and specialized testing labs.

How could Waters’ merger with BD enable the clinical adoption of LC-MS platforms in high-volume diagnostic workflows?

Waters has long been a leader in mass spectrometry and chromatographic analysis, but regulatory complexity and slow market education have kept LC-MS from breaking into hospital settings. Now, with BD’s clinical infrastructure—spanning microbiology labs, oncology testing, and molecular diagnostics—Waters gains a ready-made channel to place its instruments and consumables where clinical need meets commercial scale. Analysts believe that combining BD’s deep ties to hospital procurement networks with Waters’ proven Empower software and LC-MS technology could accelerate adoption in areas like therapeutic drug monitoring, infectious disease panels, and even early-stage cancer diagnostics.

The move aligns with a growing industry push to replace legacy immunoassay platforms with more precise, multiplex-ready technologies. Waters’ LC-MS systems can offer superior sensitivity and specificity, especially for low-abundance analytes and emerging biomarkers. However, the roadblock has often been ease-of-use, instrument uptime, and compliance with CLIA and IVD regulatory standards. With BD’s regulatory muscle and diagnostic engineering pipeline, Waters now has the opportunity to bridge those gaps and deliver turnkey solutions optimized for clinical labs—not just research institutions.

Why is the timing right for LC-MS to enter clinical diagnostics—and how does BD accelerate that timeline?

The clinical diagnostics market is evolving rapidly, driven by rising demand for precision medicine, tighter reimbursement models, and post-COVID investments in decentralized testing. Hospital labs are under pressure to automate, multiplex, and minimize error margins—factors that play to LC-MS strengths when paired with robust workflow support. BD’s diagnostics division brings with it decades of experience in clinical trial validation, assay menu expansion, and regulatory submissions. This could reduce Waters’ time-to-market for new LC-MS-based tests and help standardize their deployment across major health systems.

Experts also point to BD’s established global servicing infrastructure as a critical enabler. In many geographies, one of the key limitations for LC-MS adoption has been the lack of real-time service support. BD’s installed base across Europe, Asia, and North America could provide the local technical staffing and maintenance services necessary to make LC-MS viable at scale.

Could this be the turning point for clinical mass spectrometry adoption?

If successful, the Waters–BD merger could serve as a blueprint for how analytical chemistry tools cross into clinical diagnostics. With BD’s commercial infrastructure, regulatory depth, and point-of-care networks, Waters has a path to finally embed LC-MS into frontline hospital workflows. The next few quarters will reveal whether the combined entity can deliver on its promise of menu expansion, automation, and hospital integration. But for now, the clinical mass spectrometry conversation has shifted from “if” to “when.”